Related Experiment Video
Updated: May 5, 2026
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Bleeding risk prediction models in atrial fibrillation
Isac C Thomas1, Matthew J Sorrentino
1Department of Medicine, Section of Cardiology, University of Chicago, 5841 S. Maryland Ave, MC 6080, Chicago, IL, 60637, USA.
Insights
Novel oral anticoagulants (OACs) are effective for stroke prevention in atrial fibrillation (AF) patients. This review discusses bleeding risk models to aid clinicians in managing OAC therapy in elderly AF patients.
Area of Science:
- Cardiology
- Pharmacology
- Geriatrics
Background:
- Non-vitamin K antagonist oral anticoagulants (OACs) offer effective stroke prevention in atrial fibrillation (AF).
- The rising prevalence of AF in the elderly population presents challenges for OAC therapy initiation.
- Balancing the benefits of OACs against bleeding risks is crucial in elderly patients.
Purpose of the Study:
- To review and discuss eight bleeding risk prediction models for OAC therapy in AF patients.
- To provide clinicians with an overview of tools for assessing bleeding risk.
- To aid in the clinical decision-making process for long-term OAC treatment in the elderly.
Main Methods:
- Literature review of bleeding risk prediction models.
- Discussion of the features of models including HEMORR2HAGES, HAS-BLED, and ATRIA.
- Analysis of approaches to bleeding risk assessment in clinical practice.
Main Results:
- Several bleeding risk prediction models exist to identify high-risk patients.
- Models like HEMORR2HAGES, HAS-BLED, and ATRIA offer specific criteria for risk stratification.
- These models aim to guide clinicians in optimizing OAC therapy decisions.
Conclusions:
- Bleeding risk assessment is essential for safe and effective OAC use in AF.
- Clinicians can utilize various prediction models to personalize OAC treatment strategies.
- Careful consideration of bleeding risk is paramount, especially in the growing elderly AF population.
Abstract:
Novel, nonvitamin K antagonist oral anticoagulants (OACs) have demonstrated similar or superior efficacy to warfarin for ischemic stroke prevention in patients with atrial fibrillation (AF). As the prevalence of AF rises in a growing elderly population, these agents are becoming central to the routine practice of clinicians caring for these patients. Though the benefits are clear, the decision to treat the elderly patient with AF with long-term oral OACs is often a dilemma for the clinician mindful of the risk of major bleeding. Several bleeding risk prediction models have been created to help the clinician identify patients for whom the risk of bleeding is high, and would potentially outweigh the benefits of OAC therapy. In this review, we discuss the features of 8 bleeding risk prediction models, including the recently described HEMORR2HAGES, HAS-BLED, and ATRIA models, and approaches to assessing bleeding risk in clinical practice.
